| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 1,362 |
| Net loss | -11,386 |
| Non-cash operating lease expense | 1,074 |
| Prepaid expenses and other current assets | 588 |
| Other long-term liabilities | 31 |
| Operating lease liabilities | -1,844 |
| Deposits and other assets | -940 |
| Accrued expenses and other current liabilities | -3,119 |
| Accounts payable | -385 |
| Impairment of assets held for sale | 0 |
| Loss on disposal of property and equipment | 0 |
| Depreciation | 174 |
| Net accretion of discounts on marketable securities | 243 |
| Net cash used in operating activities | -13,984 |
| Proceeds from sale of property and equipment | 0 |
| Proceeds from sales and maturities of marketable securities | 71,065 |
| Purchases of marketable securities | 23,184 |
| Amounts loaned under note receivable | 15,000 |
| Net cash provided by (used in) investing activities | 32,881 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 18,897 |
Ikena Oncology, Inc. (IKNA)
Ikena Oncology, Inc. (IKNA)